HK1139153A1 - Quinolone compound and pharmaceutical composition - Google Patents

Quinolone compound and pharmaceutical composition

Info

Publication number
HK1139153A1
HK1139153A1 HK10105911.3A HK10105911A HK1139153A1 HK 1139153 A1 HK1139153 A1 HK 1139153A1 HK 10105911 A HK10105911 A HK 10105911A HK 1139153 A1 HK1139153 A1 HK 1139153A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
quinolone compound
quinolone
compound
pharmaceutical
Prior art date
Application number
HK10105911.3A
Other languages
English (en)
Inventor
Kenji Otsubo
Yuji Ochi
Masami Nakai
Atsushi Mori
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1139153A1 publication Critical patent/HK1139153A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK10105911.3A 2007-06-06 2010-06-14 Quinolone compound and pharmaceutical composition HK1139153A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007150819 2007-06-06
PCT/JP2008/060804 WO2008150029A1 (en) 2007-06-06 2008-06-06 Quinolone compound and pharmaceutical composition

Publications (1)

Publication Number Publication Date
HK1139153A1 true HK1139153A1 (en) 2010-09-10

Family

ID=39730840

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10105911.3A HK1139153A1 (en) 2007-06-06 2010-06-14 Quinolone compound and pharmaceutical composition

Country Status (28)

Country Link
US (5) US8269011B2 (da)
EP (1) EP2152699B1 (da)
JP (1) JP5063708B2 (da)
KR (4) KR101154613B1 (da)
CN (1) CN101679392B (da)
AR (1) AR066872A1 (da)
AT (1) ATE499368T1 (da)
AU (1) AU2008260867B2 (da)
BR (1) BRPI0812234A2 (da)
CA (1) CA2688448C (da)
CO (1) CO6270258A2 (da)
CY (1) CY1111936T1 (da)
DE (1) DE602008005137D1 (da)
DK (1) DK2152699T3 (da)
ES (1) ES2360572T3 (da)
HK (1) HK1139153A1 (da)
HR (1) HRP20110151T1 (da)
IL (1) IL201894A (da)
MX (1) MX2009013239A (da)
MY (1) MY148098A (da)
NZ (1) NZ580919A (da)
PL (1) PL2152699T3 (da)
PT (1) PT2152699E (da)
RU (1) RU2490259C2 (da)
SI (1) SI2152699T1 (da)
TW (1) TWI366565B (da)
UA (1) UA98789C2 (da)
WO (1) WO2008150029A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
US20110251180A1 (en) * 2008-12-05 2011-10-13 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical agent comprising quinolone compound
EP2370411A4 (en) * 2008-12-05 2012-10-24 Univ Oregon Health & Science COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY
US8598354B2 (en) * 2008-12-05 2013-12-03 University Of South Florida Compounds having antiparasitic or anti-infectious activity
TWI472525B (zh) * 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
KR101813296B1 (ko) * 2009-12-09 2017-12-28 바를라 비.브이. 미세 콜로이달 규산／붕산 조성물 및 생체강화 용액 및 파우더의 제조 방법
JP5769504B2 (ja) * 2010-06-04 2015-08-26 大塚製薬株式会社 医薬
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
EP3394032A4 (en) * 2015-12-21 2019-09-18 The University of Chicago COMPOUNDS AND METHODS OF TREATMENT, DETECTION AND IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT OF PARASITIC ILLNESSES BY APICOMPLEXA

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3416695A1 (de) 1984-05-05 1985-11-07 Bayer Ag, 5090 Leverkusen Amidinohydrazone von tetralin-, chromon-, thiochromon- und tretrahydrochinolin-derivaten, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5081121A (en) * 1988-05-24 1992-01-14 Tatsushi Osawa 4(1h)-quinolone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
GB9026389D0 (en) 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9125485D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
WO1994010166A1 (en) 1992-10-30 1994-05-11 Pfizer Inc. Neuroprotective 3,4-dihydro-2(1h)-quinolone compounds
FR2709489B1 (fr) 1993-08-31 1995-10-20 Adir Nouveaux dérivés de 2-(1H)-quinoléinone, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP0933351A1 (en) 1994-12-30 1999-08-04 Ligand Pharmaceuticals Incorporated Tricyclic retinoids, methods for their production and use
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
AU7165798A (en) 1997-04-28 1998-11-24 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
PL351314A1 (en) 1999-04-16 2003-04-07 Astrazeneca Ab Estrogen receptor−β ligands
BR0010308A (pt) 1999-05-06 2002-01-08 Neurogen Corp Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada
FR2797444B1 (fr) 1999-08-13 2003-02-07 Lafon Labor Compositions pharmaceutiques comprenant des 4-quinolones
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
FR2813791B1 (fr) 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
AU2001296119A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Estrogen receptor-beta ligands
EP1368024A4 (en) 2001-03-16 2009-03-18 Novogen Res Pty Ltd TREATMENT OF RESTENOSIS
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US20050080024A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20040033480A1 (en) 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
GB0222516D0 (en) 2002-09-27 2002-11-06 Karobio Ab Novel compounds
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
JP2006522814A (ja) 2003-04-11 2006-10-05 タイゲン・バイオテクノロジー アミノキノリン化合物
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
EP1670485A4 (en) 2003-10-10 2009-03-11 Resverlogix Corp TREATMENT OF ILLNESSES ASSOCIATED WITH THE EGR-1 AMPLIFIER ELEMENT
JP2007525485A (ja) 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
KR100636423B1 (ko) 2004-04-30 2006-10-19 한국화학연구원 신규한 퀴놀리논 유도체, 이의 제조방법 및 이를유효성분으로 하는 약학적 조성물
US7935714B2 (en) * 2004-05-18 2011-05-03 Bright Future Pharmaceutical Laboratories Compositions for sleeping disorders
GB0420702D0 (en) * 2004-09-17 2004-10-20 Univ Birmingham Use of methanofullerene derivatives as resist materials and method for forming a resist layer
EP2332527A3 (en) 2004-10-20 2011-11-16 Resverlogix Corp. Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
EP1886996A1 (en) 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009053799A1 (en) 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
TWI472525B (zh) * 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
US20110251180A1 (en) * 2008-12-05 2011-10-13 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical agent comprising quinolone compound

Also Published As

Publication number Publication date
MX2009013239A (es) 2010-01-25
IL201894A (en) 2013-07-31
KR101154613B1 (ko) 2012-06-08
RU2490259C2 (ru) 2013-08-20
EP2152699A1 (en) 2010-02-17
AR066872A1 (es) 2009-09-16
KR20100028093A (ko) 2010-03-11
ATE499368T1 (de) 2011-03-15
CA2688448C (en) 2015-11-24
IL201894A0 (en) 2010-06-16
CO6270258A2 (es) 2011-04-20
CA2688448A1 (en) 2008-12-11
SI2152699T1 (sl) 2011-05-31
BRPI0812234A2 (pt) 2014-12-16
NZ580919A (en) 2011-12-22
US20150218101A1 (en) 2015-08-06
US9403773B2 (en) 2016-08-02
KR101472262B1 (ko) 2014-12-11
US20140121207A1 (en) 2014-05-01
CY1111936T1 (el) 2015-11-04
DE602008005137D1 (de) 2011-04-07
MY148098A (en) 2013-02-28
DK2152699T3 (da) 2011-04-18
ES2360572T3 (es) 2011-06-07
UA98789C2 (ru) 2012-06-25
JP2010528982A (ja) 2010-08-26
US8642619B2 (en) 2014-02-04
KR101403817B1 (ko) 2014-06-03
KR20120012987A (ko) 2012-02-13
JP5063708B2 (ja) 2012-10-31
US20160304461A1 (en) 2016-10-20
HRP20110151T1 (hr) 2011-05-31
AU2008260867A1 (en) 2008-12-11
TW200900382A (en) 2009-01-01
AU2008260867B2 (en) 2011-03-17
CN101679392A (zh) 2010-03-24
KR20140097570A (ko) 2014-08-06
US9045464B2 (en) 2015-06-02
EP2152699B1 (en) 2011-02-23
RU2009149612A (ru) 2011-07-20
US20100130546A1 (en) 2010-05-27
PT2152699E (pt) 2011-04-04
KR101536883B1 (ko) 2015-07-14
WO2008150029A1 (en) 2008-12-11
US8269011B2 (en) 2012-09-18
CN101679392B (zh) 2012-05-30
KR20140021723A (ko) 2014-02-20
TWI366565B (en) 2012-06-21
PL2152699T3 (pl) 2011-07-29
US20120316168A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
IL289165B2 (en) Modified azole-dione compounds and pharmaceutical preparations containing them
ZA201002547B (en) Heterocyclic compound and pharmaceutical composition thereof
HK1145461A1 (en) Benzodiazepine compound and pharmaceutical composition
IL200885A (en) A history of mannich-based compounds and pharmacological preparations including them
AP2920A (en) Anti-malarial pharmaceutical composition
HK1139153A1 (en) Quinolone compound and pharmaceutical composition
IL232457A0 (en) Quinolone compound and pharmaceutical preparation
HUS2000053I1 (hu) Kinolinszármazékok és gyógyászati készítményeik
EP2070919A4 (en) SPIROCHINONE COMPOUND AND PHARMACEUTICAL COMPOSITION
EP2114404A4 (en) COMPOUND AND PHARMACEUTICAL COMPOSITION
GB0617340D0 (en) Anti-malarial pharmaceutical composition
AU2007904647A0 (en) Pharmaceutical Compound and Composition

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE ENGLISH NAME OF THE INVENTOR FROM KEIJI OTSUBO TO KENJI OTSUBO

Effective date: 20120328

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180606